Endometrial karsinom ve endometrial intraepitelial neoplazilerde Wilms tümör 1 proteini ekspresyonu
Loading...
Files
Date
2011
Authors
Atik, Yeliz
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Son yıllarda yapılan çalışmalarda endometrial karsinom ve uterin sarkomlarda wilms tümör (WT) 1 proteini üretiminin fazla olduğu immünohistokimyasal ve genetik testlerle gösterilmiştir. Bu nedenle WT1 proteini endometrial karsinomlarda immünoterapi için düşünülen tümörle ilişkili proteinlerden biridir. Bu çalışma Endometrial İntraepitelyal Neoplazi (EİN) ve endometrial karsinomlarda WT1 proteini ekspresyonu düzeyinin gösterilmesini amaçlamaktadır.Çalışmada 30 endometrial adenokarsinom ve 20 endometrial intraepitelyal neoplazi olgusunda immunohistokimyasal olarak WT1 proteini ekspresyonu araştırıldı. Karşılaştırmak amacıyla proliferatif endometrium (n=7), sekretuar endometrium (n=9), atrofik endometrium (n= 9) ve benign endometrial polip (n=28) olguları da WT1 ekspresyonu açısından immunohistokimyasal olarak incelendi. Dokuların hücresel boyanma ve vasküler boyanması değerlendirildi.Çalışmamızda EİN vakalarında hücresel boyanma %100, vasküler boyanma %85, toplam boyanma %100 olarak saptanmıştır. Endometrioid adenokarsinom olgularında hücresel boyanma %66,6, vasküler boyanma %73,3, toplam boyanma %100 olarak saptanmıştır. Gruplar arasında hücresel boyanma pozitifliği açısından istatistiksel olarak anlamlı bir farklılık saptanmıştır (p=0,012).Gruplar arasında vasküler ve toplam boyanma açısından istatistiksel olarak anlamlı bir farklılık saptanmamıştır (p=0,608, p>0,05). Endometrioid adenokarsinom olgularında grade ve evre artışı ile vasküler, hücresel ve toplam boyanma artışı arasında anlamlı korelasyon saptanmamıştır.Sonuç olarak endometrioid adenokarsinom ve EİN olgularında yüksek WT1 boyanma oranları görülmektedir ve bu olgularda, tümör ilişkili antijen olan WT1 proteinini hedef alan immunoterapi uygulanabilir bir tedavi seçeneği olabilir.
Recent immunohistochemical and genetic studies showed wilms tumor (WT)1 protein overexpression in endometrial carcinomas and uterine sarcomas. WT1 protein is a tumor associated antigen that might be considered for endometrial cancer immunotherapy. The objective of this study was to investigate expression level of WT1 protein in endometrial carcinomas and Endometrial Intraepithelial Neoplasias (EİN) by immunohistochemistry.WT1 expression was determined immunohistochemically in 30 endometrial adenocarcinoma and 20 EIN patients. WT1 expression levels in proliferative (n=7), secretory (n=9) and atrophic endometrium (n= 9) and benign endometrial polyps (n=28) were used for comparison. Staining of tumor cells and vascular endothelium were evaluated.The cellular staining of EIN cases was 100%, vascular staining was 85% and total positivity was 100%. WT1 positivity was found in 66.6% of tumor cells, 73.3% of endothelium and totally 100% of endometrioid adenocarcinomas. Ther was a significant difference between the groups in means of cellular staining positivity. (p=0,012). Vascular endothelial staining and total WT1 positivity did not differ between the groups (p=0,608, p>0,05). Cellular, endothelial and total WT1 expression did not correlate with histological grade and stage in endometrial cancer.We showed that WT1 is overexpressed in endometrial carcinoma and EİN, suggesting that immunotherapy targeting the WT1 protein might be applicable in these cases.
Recent immunohistochemical and genetic studies showed wilms tumor (WT)1 protein overexpression in endometrial carcinomas and uterine sarcomas. WT1 protein is a tumor associated antigen that might be considered for endometrial cancer immunotherapy. The objective of this study was to investigate expression level of WT1 protein in endometrial carcinomas and Endometrial Intraepithelial Neoplasias (EİN) by immunohistochemistry.WT1 expression was determined immunohistochemically in 30 endometrial adenocarcinoma and 20 EIN patients. WT1 expression levels in proliferative (n=7), secretory (n=9) and atrophic endometrium (n= 9) and benign endometrial polyps (n=28) were used for comparison. Staining of tumor cells and vascular endothelium were evaluated.The cellular staining of EIN cases was 100%, vascular staining was 85% and total positivity was 100%. WT1 positivity was found in 66.6% of tumor cells, 73.3% of endothelium and totally 100% of endometrioid adenocarcinomas. Ther was a significant difference between the groups in means of cellular staining positivity. (p=0,012). Vascular endothelial staining and total WT1 positivity did not differ between the groups (p=0,608, p>0,05). Cellular, endothelial and total WT1 expression did not correlate with histological grade and stage in endometrial cancer.We showed that WT1 is overexpressed in endometrial carcinoma and EİN, suggesting that immunotherapy targeting the WT1 protein might be applicable in these cases.
Description
Keywords
Endometrial intraepitelyal neoplazi, WT1 proteini, Endometrial intraepithelial neoplasia, WT1 protein
Citation
Atik, Y. (2011). Endometrial karsinom ve endometrial intraepitelial neoplazilerde Wilms tümör 1 proteini ekspresyonu. Yayınlanmamış uzmanlık tezi. Uludağ Üniversitesi Tıp Fakültesi.